ARS Pharmaceuticals Inc. (SPRY)
| Bid | 14.21 |
| Market Cap | 1.4B |
| Revenue (ttm) | 89.15M |
| Net Income (ttm) | 8M |
| EPS (ttm) | 0.08 |
| PE Ratio (ttm) | 177.88 |
| Forward PE | -25.42 |
| Analyst | Buy |
| Ask | 14.23 |
| Volume | 673,295 |
| Avg. Volume (20D) | 1,654,568 |
| Open | 13.83 |
| Previous Close | 13.97 |
| Day's Range | 13.49 - 14.23 |
| 52-Week Range | 7.55 - 18.51 |
| Beta | 0.98 |
About SPRY
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California....
Analyst Forecast
According to 4 analyst ratings, the average rating for SPRY stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 103.79% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges AwaitARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's co...
2 months ago · seekingalpha.com
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic ReactionsARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Neffy's early sales also beat expectations, which I think showcases how mu...